Humer may be dead set against a deal, but Novartis Chief Executive Daniel Vasella is a patient man.

FORBES: Health

Thanks in part to a hot new hepatitis drug called Pegasys, Roche is staging an unlikely revival, giving Chairman Franz Humer some much-needed breathing room.

FORBES: Back From the Morgue

Roche's Humer promises Roche can return to glory without a merger.

FORBES: Back From the Morgue

Humer argues that it is relatively easy to hire more sales reps or ink a comarketing contract with another drug firm that has a big U.S. sales force.

FORBES: Magazine Article

In the meantime Humer is counting on a turnaround in the company's far-flung research labs, orchestrated by research head Jonathan Knowles, hired by Humer from Glaxo Wellcome in 1997.

FORBES: Magazine Article

Although the number given was only the total amount paid to its directors--we still had to estimate the pay of the CEO, Franz Humer--it is a step in the right direction.

FORBES: The top of the heap

Any successor to Humer will benefit as a result.

FORBES: Is Apple/Genentech's Art Levinson Poised to Assume Chairman Role at Roche?